132 related articles for article (PubMed ID: 7854165)
1. Insulinotropic action of human glicentin in dogs.
Ohneda A; Ohneda K; Nagasaki T; Sasaki K
Metabolism; 1995 Jan; 44(1):47-51. PubMed ID: 7854165
[TBL] [Abstract][Full Text] [Related]
2. Effect of glicentin-related peptides upon the secretion of insulin and glucagon in the canine pancreas.
Ohneda A; Ohneda M
Tohoku J Exp Med; 1988 Jun; 155(2):197-204. PubMed ID: 3062845
[TBL] [Abstract][Full Text] [Related]
3. Effect of glicentin-related peptides on glucagon secretion in anaesthetized dogs.
Ohneda A; Kobayashi T; Nihei J
Diabetologia; 1986 Jun; 29(6):397-401. PubMed ID: 3527839
[TBL] [Abstract][Full Text] [Related]
4. Effect of C-terminal fragments of glucagon on insulin secretion in dogs.
Ohneda A; Ohneda K
Metabolism; 1994 Jun; 43(6):771-5. PubMed ID: 8201969
[TBL] [Abstract][Full Text] [Related]
5. Effect of intraluminal administration of amino acids upon plasma glicentin.
Ohneda A; Kobayashi T; Nihei J; Takahashi H
Diabetes Res Clin Pract; 1988 Oct; 5(4):265-70. PubMed ID: 3069408
[TBL] [Abstract][Full Text] [Related]
6. The structure-function relationship of GLP-1 related peptides in the endocrine function of the canine pancreas.
Ohneda A; Ohneda K; Ohneda M; Koizumi F; Ohashi S; Kawai K; Suzuki S
Tohoku J Exp Med; 1991 Nov; 165(3):209-21. PubMed ID: 1807008
[TBL] [Abstract][Full Text] [Related]
7. Insulin releasing action of N-terminal peptides of glucagon in dogs.
Ohneda A; Ohneda K; Koizumi F
Tohoku J Exp Med; 1992 Aug; 167(4):287-95. PubMed ID: 1488751
[TBL] [Abstract][Full Text] [Related]
8. Response of plasma glicentin to intraduodenal administration of glucose in piglets.
Ohneda A
Diabetes Res Clin Pract; 1987; 3(2):97-102. PubMed ID: 3568997
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.
Pørksen N; Grøfte B; Nyholm B; Holst JJ; Pincus SM; Veldhuis JD; Schmitz O; Butler PC
Diabetes; 1998 Jan; 47(1):45-9. PubMed ID: 9421373
[TBL] [Abstract][Full Text] [Related]
10. Plasma glicentin in diabetic and gastrectomized patients.
Naito H; Ohneda A; Kojima R; Sato T; Sasaki K; Funayama Y; Fukushima K; Shibata C; Matsuno S; Sasaki I
Regul Pept; 1999 Jan; 79(1):55-61. PubMed ID: 9930583
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
[TBL] [Abstract][Full Text] [Related]
12. Extrapancreatic action of truncated glucagon-like peptide-I in Otsuka Long-Evans Tokushima Fatty rats, an animal model for non-insulin-dependent diabetes mellitus.
Mizuno A; Kuwajima M; Ishida K; Noma Y; Murakami T; Tateishi K; Sato I; Shima K
Metabolism; 1997 Jul; 46(7):745-9. PubMed ID: 9225826
[TBL] [Abstract][Full Text] [Related]
13. Response of plasma glicentin to fat ingestion in piglets.
Ohneda A; Takahashi H; Maruyama Y
Diabetes Res Clin Pract; 1987; 3(2):103-9. PubMed ID: 3552536
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
[TBL] [Abstract][Full Text] [Related]
15. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
[TBL] [Abstract][Full Text] [Related]
16. Contraction induced by glicentin on smooth muscle cells from the human colon is abolished by exendin (9-39).
Ayachi SE; Borie F; Magous R; Sasaki K; le Nguyen D; Bali JP; Millat B; Jarrousse C
Neurogastroenterol Motil; 2005 Apr; 17(2):302-9. PubMed ID: 15787950
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
Sandhu H; Wiesenthal SR; MacDonald PE; McCall RH; Tchipashvili V; Rashid S; Satkunarajah M; Irwin DM; Shi ZQ; Brubaker PL; Wheeler MB; Vranic M; Efendic S; Giacca A
Diabetes; 1999 May; 48(5):1045-53. PubMed ID: 10331409
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biochemical characterization of proglucagon-related peptides.
Yanaihara N; Mochizuki T; Satoh T; Imai S; Sasaki K; Kakuyama H; Hosoe H; Takatsuka N; Iguchi K; Luo WQ; Kurokawa N; Yanaihara C
Ann N Y Acad Sci; 1996 Dec; 805():20-9; discussion 29-30. PubMed ID: 8993390
[No Abstract] [Full Text] [Related]
20. Effect of glucagon, glicentin, glucagon-like peptide-1 and -2 on interdigestive gastroduodenal motility in dogs with a vagally denervated gastric pouch.
Shibata C; Naito H; Jin XL; Ueno T; Funayama Y; Fukushima K; Hashimoto A; Matsuno S; Sasaki I
Scand J Gastroenterol; 2001 Oct; 36(10):1049-55. PubMed ID: 11589377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
